LASA Policy/ list updates for Biosimilars/ Monoclonals

PLEASE NOTE:   Posts made to this forum should not be considered as the expressed opinions of, nor should be considered endorsed by, the Medication Safety Officer’s Society (MSOS) or the Institute for Safe Medication Practices (ISMP). 

Make sure your email is up-to-date
In order to continue to receive updates from MSOS, as well as forum posts and other valuable information as a member of MSOS, please be sure to update your email address with us, whenever it changes. If you need assistance doing so, please send an email to jrufo@ismp.org. 

2 posts / 0 new
Log in or register to post comments
Last post
Tue, 12/12/2023 - 09:59
#1
Leah Cochran
Leah Cochran's picture
Offline
Last seen: 1 week 12 hours ago
Joined: 11/15/2023 - 15:26
LASA Policy/ list updates for Biosimilars/ Monoclonals

Can anyone share how they have tackled their LASA policy/lists when it comes to addressing biosimilars and monoclonal antibodies. We think the nomenclature is easily confused and are evaluating possible safety impacts/look-alike, sound-alike risks as more of these products come to market. We would prefer to avoid blanket statements such as adding all monoclonal antibodies are at risk for LASA errors.
Thanks!

Tags: 

Top